115 related articles for article (PubMed ID: 31264550)
21. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis.
Suzuki E; Umezawa K; Bonavida B
Oncogene; 2007 Sep; 26(42):6184-93. PubMed ID: 17420722
[TBL] [Abstract][Full Text] [Related]
22. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma.
Woodard J; Sassano A; Hay N; Platanias LC
Clin Cancer Res; 2008 Jul; 14(14):4640-9. PubMed ID: 18628479
[TBL] [Abstract][Full Text] [Related]
23. Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs.
Roudier E; Mistafa O; Stenius U
Mol Cancer Ther; 2006 Nov; 5(11):2706-15. PubMed ID: 17121917
[TBL] [Abstract][Full Text] [Related]
24. Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT/β-catenin and AKT/GSK3β proliferative signaling.
Chung J; Karkhanis V; Baiocchi RA; Sif S
J Biol Chem; 2019 May; 294(19):7692-7710. PubMed ID: 30885941
[TBL] [Abstract][Full Text] [Related]
25. Physiological functions of CKIP-1: From molecular mechanisms to therapy implications.
Fu L; Zhang L
Ageing Res Rev; 2019 Aug; 53():100908. PubMed ID: 31082489
[TBL] [Abstract][Full Text] [Related]
26. Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation.
Chapuy B; Schuelper N; Panse M; Dohm A; Hand E; Schroers R; Truemper L; Wulf GG
Br J Haematol; 2011 Feb; 152(4):401-12. PubMed ID: 21689083
[TBL] [Abstract][Full Text] [Related]
27. Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease.
Nguyen PL; Harris NL; Ritz J; Robertson MJ
Am J Pathol; 1996 Mar; 148(3):847-53. PubMed ID: 8774139
[TBL] [Abstract][Full Text] [Related]
28. ENO1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphomas.
Zhu X; Miao X; Wu Y; Li C; Guo Y; Liu Y; Chen Y; Lu X; Wang Y; He S
Exp Cell Res; 2015 Jul; 335(2):216-23. PubMed ID: 26024773
[TBL] [Abstract][Full Text] [Related]
29. Statins induce apoptosis through inhibition of Ras signaling pathways and enhancement of Bim and p27 expression in human hematopoietic tumor cells.
Fujiwara D; Tsubaki M; Takeda T; Tomonari Y; Koumoto YI; Sakaguchi K; Nishida S
Tumour Biol; 2017 Oct; 39(10):1010428317734947. PubMed ID: 28990465
[TBL] [Abstract][Full Text] [Related]
30. An analysis of the effect of statins on the risk of Non-Hodgkin's Lymphoma in the Women's Health Initiative cohort.
Desai P; Wallace R; Anderson ML; Howard BV; Ray R; Wu C; Safford M; Martin LW; Schlecht N; Liu S; Cirillo D; Jay A; Manson JE; Simon MS
Cancer Med; 2018 May; 7(5):2121-2130. PubMed ID: 29608241
[TBL] [Abstract][Full Text] [Related]
31. Relationship between Hodgkin's and non-Hodgkin's lymphomas.
Amini RM; Enblad G
Med Oncol; 2003; 20(3):211-20. PubMed ID: 14514970
[TBL] [Abstract][Full Text] [Related]
32. Statins prevent pulsatile stretch-induced proliferation of human saphenous vein smooth muscle cells via inhibition of Rho/Rho-kinase pathway.
Kozai T; Eto M; Yang Z; Shimokawa H; Lüscher TF
Cardiovasc Res; 2005 Dec; 68(3):475-82. PubMed ID: 16098957
[TBL] [Abstract][Full Text] [Related]
33. CD150-mediated Akt signalling pathway in normal and malignant B cells.
Yurchenko M; Shlapatska LM; Romanets OL; Ganshevskiy D; Kashuba E; Zamoshnikova A; Ushenin YV; Snopok BA; Sidorenko SP
Exp Oncol; 2011 Mar; 33(1):9-18. PubMed ID: 21423089
[TBL] [Abstract][Full Text] [Related]
34. FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.
Szydlowski M; Kiliszek P; Sewastianik T; Jablonska E; Bialopiotrowicz E; Gorniak P; Polak A; Markowicz S; Nowak E; Grygorowicz MA; Prochorec-Sobieszek M; Szumera-Cieckiewicz A; Malenda A; Lech-Maranda E; Warzocha K; Juszczynski P
Blood; 2016 Feb; 127(6):739-48. PubMed ID: 26585955
[TBL] [Abstract][Full Text] [Related]
35. The interrelationship between Hodgkin's disease and non-Hodgkin's lymphomas.
Jaffe ES; Zarate-Osorno A; Kingma DW; Raffeld M; Medeiros LJ
Ann Oncol; 1994; 5 Suppl 1():7-11. PubMed ID: 8172822
[TBL] [Abstract][Full Text] [Related]
36. Expression of Akt (protein kinase B) and its isoforms in malignant lymphomas.
Fillmore GC; Wang Q; Carey MJ; Kim CH; Elenitoba-Johnson KS; Lim MS
Leuk Lymphoma; 2005 Dec; 46(12):1765-73. PubMed ID: 16263580
[TBL] [Abstract][Full Text] [Related]
37. HMG-CoA reductase inhibitors promote cholesterol-dependent Akt/PKB translocation to membrane domains in endothelial cells.
Skaletz-Rorowski A; Lutchman M; Kureishi Y; Lefer DJ; Faust JR; Walsh K
Cardiovasc Res; 2003 Jan; 57(1):253-64. PubMed ID: 12504836
[TBL] [Abstract][Full Text] [Related]
38. CKIP-1 augments autophagy in steatotic hepatocytes by inhibiting Akt/mTOR signal pathway.
Li L; Xie P; Lin W; Liu J; Chen J; Guo Z; Bin C; An W; Zhang C; Zhan Y
Exp Cell Res; 2020 Dec; 397(1):112341. PubMed ID: 33191205
[TBL] [Abstract][Full Text] [Related]
39. [Expression and correlation of Skp2 and p27(kip1) in 92 cases of non-Hodgkin's lymphoma].
Lu JX; Zhang DM; Shen AG; Wang YC; He S; Shao XY; Liu HO; Cheng C
Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):373-7. PubMed ID: 17892135
[TBL] [Abstract][Full Text] [Related]
40. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
Nguyen T; Parker R; Hawkins E; Holkova B; Yazbeck V; Kolluri A; Kmieciak M; Rahmani M; Grant S
Oncotarget; 2017 May; 8(19):31478-31493. PubMed ID: 28416758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
